Home > > > Global Peptic Ulcer Market to Surge from USD 15.0 Billion in 2025 to USD 31.2 Billion by 2032 at 8.9

Global Peptic Ulcer Market to Surge from USD 15.0 Billion in 2025 to USD 31.2 Billion by 2032 at 8.9

Author : pratiksha mmr | Published On : 17 Aug 2026

Global Peptic Ulcer Market to Surge from USD 15.0 Billion in 2025 to USD 31.2 Billion by 2032 at 8.9% CAGR.

Global Peptic Ulcer Market is entering a high-growth phase as rising disease prevalence, aging populations, increasing healthcare expenditure, pharmaceutical innovation, and expanding access to gastrointestinal care reshape the treatment landscape. According to Maximize Market Research, the market was valued at USD 15.0 billion in 2025 and is projected to reach USD 31.2 billion by 2032, expanding at a CAGR of 8.9% during 2026–2032. The growth outlook reflects increasing patient volumes, lifestyle-related risk factors, NSAID consumption, H. pylori infections, healthcare infrastructure investment, and expanding research and development activity.

Request a Free Sample of Full Market Report Link: https://www.maximizemarketresearch.com/request-sample/71854/ 

Peptic Ulcer Treatment Moves Toward Precision and Patient-Centric Healthcare

Peptic ulcer disease is increasingly being addressed through more targeted treatment strategies. Proton pump inhibitors (PPIs), H2 antagonists, antacids, and antibiotics remain central to treatment, particularly where H. pylori infection is involved. At the same time, growing research into pathogen-specific treatment, personalized medicine, and improved eradication strategies is creating new opportunities for pharmaceutical companies.

MMR highlights next-generation sequencing as a potential tool for monitoring H. pylori virulence determinants, supporting the longer-term development of personalized treatment and patient-management approaches. Increasing R&D activity, product launches, collaborative agreements, and product updates are also strengthening innovation momentum across the market.

Get Free Sample of Full Market Report Link: https://www.maximizemarketresearch.com/market-report/global-peptic-ulcer-market/71854/ 

Market Segmentation: PPI and Gastric Ulcer Applications Lead

MMR's market structure identifies three principal dimensions:

By Drug Type

  • Proton Pump Inhibitors (PPI): Dominating the market with the highest CAGR during the forecast period, supported by their effectiveness in reducing acid secretion, inflammation, and ulcer-related discomfort.

  • H2 Antagonists

  • Antacids

  • Others

By Ulcer Type

  • Gastric Ulcer: Leading segment, supported by the high prevalence of stomach ulcers.

  • Duodenal Ulcer

By Distribution Channel

  • Hospital Pharmacies: Dominating the market, supported by expanding hospital networks and the availability of integrated healthcare services.

  • Retail Pharmacies

  • Online Pharmacies

AI-Driven Diagnostics and Digital Health Reshape Gastrointestinal Care

The next phase of gastrointestinal healthcare is increasingly connected to AI-assisted diagnostics, digital clinical workflows, smart endoscopy, and data-driven decision support. Recent research demonstrates this direction: a 2025 multicenter study reported that an AI-assisted endoscopic system improved identification of ulcerative lesions and reduced interpretation time, illustrating the potential for AI to support more efficient gastrointestinal diagnostics.

The broader innovation ecosystem also includes AI-based endoscopic research, genomics-enabled H. pylori characterization, digital patient monitoring, and increasingly data-driven clinical research. These developments can complement pharmaceutical innovation by enabling earlier detection, improved disease classification, and more personalized treatment pathways.

FDA-Backed Innovation Strengthens the Treatment Pipeline

Regulatory progress is another important component of the evolving peptic-ulcer ecosystem. The U.S. FDA approved VOQUEZNA Triple Pak and VOQUEZNA Dual Pak in 2022 for treatment of H. pylori infection in adults. The therapies combine vonoprazan with antibiotics and were supported by clinical evidence involving 992 adult patients across 103 sites.

The continued presence of vonoprazan-based therapies in FDA records underscores the industry's shift toward alternative acid-suppression mechanisms and combination approaches for H. pylori management. Meanwhile, clinical research continues to examine eradication strategies amid antimicrobial-resistance concerns, including studies evaluating alternative combination regimens.

Regional Growth Story: USA, UK, Germany, Japan, South Korea, China and India

USA: North America held the leading regional position, supported by high healthcare expenditure, sophisticated infrastructure, treatment awareness, and strong R&D activity.

UK: The UK is covered within MMR's European analysis, where established healthcare infrastructure and pharmaceutical capabilities support demand for advanced gastrointestinal treatment.

Germany: Germany represents a significant European market within the MMR regional framework, benefiting from developed healthcare infrastructure and research capabilities.

Japan: Japan is included among the key Asia-Pacific markets, with its aging population and advanced healthcare environment supporting long-term gastrointestinal treatment demand.

South Korea: South Korea forms part of MMR's Asia-Pacific country analysis, with healthcare modernization and pharmaceutical innovation creating opportunities for advanced ulcer therapies.

China: China is one of the principal Asia-Pacific markets covered by MMR. Its large population, increasing health awareness, lifestyle-related disorders, and H. pylori burden contribute to the region's growth opportunity.

India: India is also a key Asia-Pacific market, with a large patient population, rising healthcare awareness, expanding healthcare access, and ongoing clinical research creating opportunities for pharmaceutical and digital-health solutions.

MMR further identifies Canada, Mexico, France, Italy, Spain, Sweden, Australia, ASEAN countries, Brazil, Argentina, South Africa, Egypt, Nigeria, and GCC markets within its geographic assessment.

Competitive Landscape: Global Pharmaceutical Leaders

MMR identifies major participants including Abbott Laboratories, AstraZeneca PLC, Zydus Cadila, Daewoong Pharmaceutical, Eisai, Pharmaking, Taiho Pharmaceutical, Takeda Pharmaceutical, Yuhan Corporation, GlaxoSmithKline, Novartis, Daiichi Sankyo, Boehringer Ingelheim, Sanofi, and Pfizer. Competitive strategies include product launches, collaborative agreements, product updates, R&D investment, and expansion into emerging markets.

Future Opportunities Across the Peptic Ulcer Ecosystem

The market's future will be shaped by the intersection of precision medicine, H. pylori eradication, biotechnology, AI-powered diagnostics, digital healthcare, pharmaceutical innovation, clinical research, and patient-centric treatment. Opportunities are particularly significant in personalized therapies, antimicrobial-resistance management, advanced diagnostic platforms, online pharmacy infrastructure, and emerging healthcare markets.

However, treatment costs, generic-drug availability, medication adherence, shortages of skilled professionals, limited healthcare infrastructure, regulatory requirements, and insufficient public awareness remain important constraints.

Strategic Outlook

The Global Peptic Ulcer Market is moving beyond conventional acid-suppression therapy toward a more connected healthcare model in which precision diagnostics, pharmaceutical innovation, genomics, AI-assisted clinical decision-making, and patient-centric care can increasingly work together. For pharmaceutical companies, biotech innovators, healthcare investors, and technology providers, the opportunity lies in identifying high-growth therapy categories, strengthening regional access, and building differentiated gastrointestinal-care platforms.

Maximize Market Research provides strategic intelligence for organizations seeking to understand market dynamics, competitive positioning, healthcare investment opportunities, regional expansion priorities, and emerging opportunities across the global peptic ulcer treatment ecosystem. Its research can support strategic planning, investment analysis, competitive benchmarking, and regional opportunity mapping for stakeholders preparing for the next phase of healthcare transformation.

Peptic Ulcer Market https://www.maximizemarketresearch.com/request-sample/71854/ 

Global Coagulation Testing Market https://www.maximizemarketresearch.com/request-sample/85316/ 

Global Angiographic Catheters Market https://www.maximizemarketresearch.com/request-sample/13132/ 

About Maximize Market Research 

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
+91 9607365656
[email protected]